Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 Jun;51(5):1378-1381.
doi: 10.1016/j.transproceed.2019.03.019. Epub 2019 May 2.

Everolimus-based Immunosuppression Possibly Suppresses Mean Fluorescence Intensity Values of De Novo Donor-specific Antibodies After Primary Kidney Transplantation

Shunji Narumi  1 , Yoshihiko Watarai  2 , Norihiko Goto  3 , Takahisa Hiramitsu  2 , Makoto Tsujita  3 , Manabu Okada  2 , Kenta Futamura  3 , Toshihide Tomosugi  2 , Morikuni Nishihira  4 , Shintarou Sakamoto  5 , Takaaki Kobayashi  6
Affiliations
Clinical Trial

Everolimus-based Immunosuppression Possibly Suppresses Mean Fluorescence Intensity Values of De Novo Donor-specific Antibodies After Primary Kidney Transplantation

Shunji Narumi et al. Transplant Proc. 2019 Jun.

Erratum in

  • Erratum.
    [No authors listed] [No authors listed] Transplant Proc. 2019 Jun;51(5):1636. doi: 10.1016/j.transproceed.2019.04.017. Epub 2019 May 7. Transplant Proc. 2019. PMID: 31076154 No abstract available.

Abstract

Purpose: We evaluated de novo donor-specific antibody (DSA) production of everolimus (EVR)-based immunosuppression for primary kidney transplant recipients involved in the A1202 study at our institute.

Methods: From March 2008 to August 2009, 24 recipients were prospectively randomized into 2 groups. The EVR group received reduced cyclosporin A and EVR. The standard protocol (STD) group received standard cyclosporin A and mycophenolate mofetil. Both groups received basiliximab and steroids. De novo DSA was identified using LABScreen single antigen beads (One Lambda, Canoga Park, Calif., United States). Mean fluorescence intensity (MFI) values > 1000 were considered positive. P < .05 was considered significant.

Results: Graft survival was 100% in the EVR group and 90.9% in the STD group. All patients remained on the primary protocol in the EVR group, but 3 patients in the STD group (27.3%) were converted to tacrolimus due to DSA and non-adherence. Estimated glomerular filtration rate was similar in both groups. No EVR group recipients and 9.1% of STD group recipients were treated for T-cell-mediated rejection. No recipients of the EVR group exhibited peritubular capillaritis, while 9.1% in STD group developed chronic active antibody-mediated rejection. LABScreen revealed an accumulative class II DSA production rate of 15.4% in the EVR group and 18.3% in the STD group at 10 years. When the MFI cut-off level was set to 6000, anti-HLA antibody and de novo DSA-free survival was significantly better in the EVR group.

Conclusions: EVR-based immunosuppression provided equivalent or even better clinical outcomes. EVR suppressed de novo DSA production at 10 years follow-up; however, further follow-up is inevitable.

PubMed Disclaimer

Publication types